Maxim Group Sticks to Its Buy Rating for Zivo Bioscience (ZIVO)

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Zivo Bioscience (ZIVOResearch Report) yesterday and set a price target of $9.00. The company’s shares opened today at $4.46.

Vendetti covers the Healthcare sector, focusing on stocks such as Aethlon Medical, ReShape Lifesciences, and Nephros. According to TipRanks, Vendetti has an average return of 1.1% and a 35.42% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zivo Bioscience with a $9.00 average price target.

See the top stocks recommended by analysts >>

Based on Zivo Bioscience’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.07 million. In comparison, last year the company had a GAAP net loss of $1.85 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zivo Bioscience, Inc. is engages in the study, development and commercialization of natural nutritional compounds and bioactive molecules from its proprietary algal strains. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.

Read More on ZIVO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed